Prevalence, multimodal imaging and genotype-phenotype assessment of trauma related subretinal fibrosis in stargardt disease

Eur J Ophthalmol. 2022 Nov;32(6):3201-3207. doi: 10.1177/11206721221093986. Epub 2022 Apr 14.

Abstract

Background and objectives: Stargardt disease produces lipofuscin accumulation predisposing to subretinal fibrosis (SRFib) after ocular trauma. Noninvasive imaging techniques allow in vivo assessment. The purpose of this study is to determine the prevalence of SRFib in a cohort of Stargardt patients, the presence of history of ocular trauma, the clinical features and possible genotype-phenotype associations in Stargardt patients with SRFib.

Methods: We evaluated retrospectively 106 Stargardt patients and analysed the multimodal imaging and the genotype of patients with SRFib.

Results: Six patients exhibited SRFib, three of them with history of ocular trauma. Multimodal imaging showed extensive SRFib principally in the temporal midperipheral retina with no fluid associated. SRFib was better defined by short wavelength autofluorescence and spectral domain optical coherence tomography and appeared clinically stable over time. There was no particular genotype associated to SRFib.

Conclusion: SRFib occurs in a significant percentage of patients with Stargardt disease and can be diagnosed through multimodal imaging regardless the history of trauma, further sustaining the importance of an appropriate imaging in such patients. No genotype-phenotype association has been established, supporting the traumatic etiology in half of cases. The remaining cases may be classified as idiopathic or have a minimal trauma occurring early in life that may be not recalled by the patients.

Keywords: Stargardt; multicolor; multimodal imaging; ocular trauma; subretinal fibrosis.

MeSH terms

  • Fibrosis
  • Fluorescein Angiography / methods
  • Humans
  • Lipofuscin*
  • Multimodal Imaging
  • Phenotype
  • Prevalence
  • Retrospective Studies
  • Stargardt Disease
  • Tomography, Optical Coherence* / methods

Substances

  • Lipofuscin